Philogen 
Welcome,         Profile    Billing    Logout  
 6 Products   27 Diseases  6 Products   18 Trials   284 News 
27 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dekavil (F8-IL10) / Pfizer
NCT02270632 / 2013-005418-37: A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX

Terminated
2
27
Europe
F8IL10, Dekavil, MTX, Methotrexate, Placebo
Philogen S.p.A.
Rheumatoid Arthritis
04/19
06/23
DekaJoint, NCT05622175: Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment

Not yet recruiting
1
32
NA
F8IL10, Dekavil
Philogen S.p.A.
Rheumatoid Arthritis
12/25
12/26
darleukin (L19IL2) / Philogen
Pivotal, NCT02938299 / 2015-002549-72: Neoadjuvant L19IL2/L19TNF- Study

Active, not recruiting
3
214
Europe
L19IL2 + L19TNF, Surgery
Philogen S.p.A.
Malignant Melanoma
10/24
12/28
2020-003299-42: Intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients

Not yet recruiting
2
92
Europe
Bifikafusp alfa, onfekafusp alfa, L19IL2, L19TNF, Solution for injection
Philogen S.p.A., Philogen S.p.A.
Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery according to the evaluation of a local interdisciplinary tumor board or who refuse surgery and for whom an histological evaluation is available according to international guidelines, Non melanoma skin cancer, Diseases [C] - Cancer [C04]
 
 
IMMUNOSABR2, NCT03705403 / 2018-002583-11: IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

Terminated
2
88
Europe
Darleukin, L19 - IL2, Radiation, Radiotherapy
Maastricht University Medical Center, Academisch Ziekenhuis Maastricht, The Netherlands Cancer Institute, University Medical Center Nijmegen, Erasmus Medical Center, University Ghent, KU Leuven, Centre Oscar Lambret, Gasthuis Zusters Antwerpen, University College, London, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, University Hospital Dresden, University Hospital Tuebingen, Heidelberg University, Catholic University of the Sacred Heart, Institut du Cancer de Montpellier - Val d'Aurelle
NSCLC Stage IV, Metastatic Disease
01/25
01/25
IntriNSiC, NCT05329792 / 2021-006041-36: L19IL2/L19TNF in Skin Cancer Patients

Recruiting
2
70
Europe
L19IL2/L19TNF, bifikafusp alfa/onfekafusp alfa
Philogen S.p.A., Philogen S.p.A.
BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma, Keratoacanthoma of Skin, Malignant Adnexal Tumors of the Skin (MATS), Tumors From Cutaneous T-cell Lymphoma (CTCL), Kaposi Sarcoma
06/24
12/24
NCT02076646: A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Active, not recruiting
1/2
96
Europe
L19IL2 - Ph I, L19IL2 at RD - Ph II, DTIC, DETICENE®
Philogen S.p.A.
Metastatic Melanoma Stage IV
05/16
06/22
NCT02957019 / 2014-001949-25: A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Terminated
1/2
6
Europe
L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab
Philogen S.p.A.
Diffuse Large B-cell Lymphoma (DLBCL)
09/23
09/23
Theratri, NCT06640413: A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination with L19-IL2 As a Treatment of Metastatic FAP-positive Solid Tumors

Not yet recruiting
1
56
Europe
[177Lu]Lu-OncoFAP-23, L19IL2
Philogen S.p.A.
FAP
05/28
12/28
teleukin (F16-IL2) / Philogen
Nivokin, NCT05468294: F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer

Active, not recruiting
1/2
3
Europe
F16IL2, Nivolumab, fixed dose
Philogen S.p.A.
Non-small Cell Lung Cancer (NSCLC)
12/21
07/22
NCT02957032: A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Terminated
1
30
Europe
F16IL2, cytarabine
Philogen S.p.A.
Acute Myeloid Leukemia, Relapsed, Adult
09/23
09/23
Fibromun (onfekafusp alfa) / Philogen
FIBROSARC, NCT04650984 / 2016-003239-38: A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Recruiting
3
102
Europe
Onfekafusp alfa, L19TNF, Doxorubicin
Philogen S.p.A.
Soft Tissue Sarcoma
12/25
12/25
2018-004104-19: A study to investigate the efficacy and safety of L19TNF in previously treated patients with advanced stage or metastatic soft-tissue sarcoma

Not yet recruiting
2
98
Europe
Onfekafusp alfa, Dacarbazin, L19TNF, Solution for injection, Powder for solution for injection/infusion, Dacarbazin
Philogen S.p.A., PHILOGEN S.P.A., Philogen S.p.A.,
Unresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens, Soft-tissue sarcoma after failure of at least two prior systemic therapy regimens, Diseases [C] - Cancer [C04]
 
 
FLASH, NCT04733183 / 2018-004104-19: Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

Active, not recruiting
2
98
Europe
Dacarbazine, DTIC, onfekafusp alfa, L19TNF
Philogen S.p.A., Philogen S.p.A.,
Soft Tissue Sarcoma
12/25
12/25
GLIOSTELLA, NCT06336291: A Study with L19TNF in Combination with Lomustine in Patients with Glioblastoma At Progression or Recurrence

Recruiting
2
90
US
L19TNF, onfekafusp alfa, Lomustine
Philogen S.p.A.
Glioblastoma
06/26
06/26
FIBROSARC USA, NCT03420014: Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients

Recruiting
2
114
US
Doxorubicin, L19TNF plus doxorubicin
Philogen S.p.A.
Leiomyosarcoma
12/24
12/25
GLIOMOON, NCT03779230: Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse

Completed
1/2
20
Europe
L19TNF, onfekafusp alpha
Philogen S.p.A.
Glioma of Brain
06/23
06/23
GLIOSTAR, NCT04573192: A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

Recruiting
1/2
142
Europe
L19TNF, onfekafusp alfa, Lomustine
Philogen S.p.A.
Glioblastoma
03/25
12/25
GLIOSUN, NCT04443010: Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma

Recruiting
1/2
226
Europe
Onfekafusp alfa, L19TNF, Temozolomide, TMZ
Philogen S.p.A.
Glioblastoma
10/26
12/26
DOXO75, NCT04032964: Dose Finding Study of L19TNF and Doxorubicin in Patients With STS

Active, not recruiting
1
2
US
L19TNF, DOXORUBICIN
Philogen S.p.A.
Soft Tissue Sarcoma
12/24
12/24
GLIOASTRA, NCT05304663: Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression

Withdrawn
1
24
NA
Onfekafusp alfa, L19TNF, Lomustine
Philogen S.p.A.
Glioblastoma
12/24
12/24
dodekin (F8-IL12) / Philogen
DODEKA, NCT04471987: Safety and Early Signs of Efficacy of IL12-L19L19.

Recruiting
1
94
Europe
IL12-L19L19, Dodekin
Philogen S.p.A.
Advanced Solid Tumor, Metastatic Solid Tumor
12/25
12/25
Nidlegy (darleukin/fibromun) / Philogen
2021-003064-27: Study of the efficacy of intratumoral injections of L19IL2 + L19TNF followed by surgery to prevent or retard appearance of new metastases Estudio de la eficacia de las inyecciones intratumorales de L19IL2 + L19TNF seguidas de cirugía para prevenir o retrasar la aparición de nuevas metástasis

Not yet recruiting
3
186
Europe
Darleukin, Onfekafusp alfa, L19IL2, L19TNF, Solution for injection
Philogen S.p.A., Philogen S.p.A.
Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions Melanoma maligno de la piel en pacientes con melanoma localmente avanzado y completamente resecable con/sin terapia previa y presencia de lesiones inyectables cutáneas y/o subcutáneas o ganglionares, Patients with metastatic melanoma, eligible for surgical resection of all metastases and with presence of injectable cutaneous, subcutaneous and/or nodal lesions. Pacientes con melanoma metastásico, aptos para resección quirúrgica de todas las metástasis y con presencia de lesiones cutáneas inyectables, subcutáneas y/o ganglionares., Diseases [C] - Cancer [C04]
 
 
Neo-DREAM, NCT03567889 / 2021-003064-27: Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients

Recruiting
3
186
Europe, US
Daromun, Surgery, Adjuvant therapy
Philogen S.p.A., Philogen S.p.A.
Melanoma Stage IIIB/C
06/24
06/26
INTACT, NCT06284590: Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

Recruiting
2
162
US
L19IL2, bifikafusp alfa, L19TNF, onfekafusp alfa, L19IL2/L19TNF, Daromun, KEYTRUDA®, pembrolizumab
Philogen S.p.A., Merck Sharp & Dohme LLC
Melanoma Stage III, Melanoma Stage IV
07/28
07/28
DUNCAN, NCT04362722 / 2020-003299-42: Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients

Recruiting
2
40
Europe
L19IL2 +L19TNF, bifikafusp alfa + onfekafusp alfa
Philogen S.p.A., Philogen S.p.A.
Carcinoma, Basal Cell, Carcinoma, Cutaneous Squamous Cell
09/24
09/24
NCT07046728: Efficay and Safety of DAROMUN on Patient Treated by Intralesionnal Injection: DAROMEL

Not yet recruiting
N/A
70
Europe
Efficay and Safety of DAROMUN on patient treated by intralesionnal injection: DAROMEL
Centre Hospitalier Universitaire de Nice
Injections Intralesional
10/25
03/26
Tripokin (IL2-L19-TNF) / Philogen
No trials found
177Lu-OncoFAP-23 / Philogen
No trials found
PHC-102 / Philogen
No trials found
ABBV-022 / AbbVie
No trials found
177Lu-BiOncoFAP / Philogen
No trials found
FAP-IL12 / Philogen
No trials found
Undisclosed prostate cancer therapeutic / Philogen
No trials found
OncoFAP-GlyPro-MMAE / Philogen
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dekavil (F8-IL10) / Pfizer
NCT02270632 / 2013-005418-37: A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX

Terminated
2
27
Europe
F8IL10, Dekavil, MTX, Methotrexate, Placebo
Philogen S.p.A.
Rheumatoid Arthritis
04/19
06/23
DekaJoint, NCT05622175: Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment

Not yet recruiting
1
32
NA
F8IL10, Dekavil
Philogen S.p.A.
Rheumatoid Arthritis
12/25
12/26
darleukin (L19IL2) / Philogen
Pivotal, NCT02938299 / 2015-002549-72: Neoadjuvant L19IL2/L19TNF- Study

Active, not recruiting
3
214
Europe
L19IL2 + L19TNF, Surgery
Philogen S.p.A.
Malignant Melanoma
10/24
12/28
2020-003299-42: Intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients

Not yet recruiting
2
92
Europe
Bifikafusp alfa, onfekafusp alfa, L19IL2, L19TNF, Solution for injection
Philogen S.p.A., Philogen S.p.A.
Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery according to the evaluation of a local interdisciplinary tumor board or who refuse surgery and for whom an histological evaluation is available according to international guidelines, Non melanoma skin cancer, Diseases [C] - Cancer [C04]
 
 
IMMUNOSABR2, NCT03705403 / 2018-002583-11: IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

Terminated
2
88
Europe
Darleukin, L19 - IL2, Radiation, Radiotherapy
Maastricht University Medical Center, Academisch Ziekenhuis Maastricht, The Netherlands Cancer Institute, University Medical Center Nijmegen, Erasmus Medical Center, University Ghent, KU Leuven, Centre Oscar Lambret, Gasthuis Zusters Antwerpen, University College, London, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, University Hospital Dresden, University Hospital Tuebingen, Heidelberg University, Catholic University of the Sacred Heart, Institut du Cancer de Montpellier - Val d'Aurelle
NSCLC Stage IV, Metastatic Disease
01/25
01/25
IntriNSiC, NCT05329792 / 2021-006041-36: L19IL2/L19TNF in Skin Cancer Patients

Recruiting
2
70
Europe
L19IL2/L19TNF, bifikafusp alfa/onfekafusp alfa
Philogen S.p.A., Philogen S.p.A.
BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma, Keratoacanthoma of Skin, Malignant Adnexal Tumors of the Skin (MATS), Tumors From Cutaneous T-cell Lymphoma (CTCL), Kaposi Sarcoma
06/24
12/24
NCT02076646: A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Active, not recruiting
1/2
96
Europe
L19IL2 - Ph I, L19IL2 at RD - Ph II, DTIC, DETICENE®
Philogen S.p.A.
Metastatic Melanoma Stage IV
05/16
06/22
NCT02957019 / 2014-001949-25: A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Terminated
1/2
6
Europe
L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab
Philogen S.p.A.
Diffuse Large B-cell Lymphoma (DLBCL)
09/23
09/23
Theratri, NCT06640413: A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination with L19-IL2 As a Treatment of Metastatic FAP-positive Solid Tumors

Not yet recruiting
1
56
Europe
[177Lu]Lu-OncoFAP-23, L19IL2
Philogen S.p.A.
FAP
05/28
12/28
teleukin (F16-IL2) / Philogen
Nivokin, NCT05468294: F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer

Active, not recruiting
1/2
3
Europe
F16IL2, Nivolumab, fixed dose
Philogen S.p.A.
Non-small Cell Lung Cancer (NSCLC)
12/21
07/22
NCT02957032: A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Terminated
1
30
Europe
F16IL2, cytarabine
Philogen S.p.A.
Acute Myeloid Leukemia, Relapsed, Adult
09/23
09/23
Fibromun (onfekafusp alfa) / Philogen
FIBROSARC, NCT04650984 / 2016-003239-38: A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Recruiting
3
102
Europe
Onfekafusp alfa, L19TNF, Doxorubicin
Philogen S.p.A.
Soft Tissue Sarcoma
12/25
12/25
2018-004104-19: A study to investigate the efficacy and safety of L19TNF in previously treated patients with advanced stage or metastatic soft-tissue sarcoma

Not yet recruiting
2
98
Europe
Onfekafusp alfa, Dacarbazin, L19TNF, Solution for injection, Powder for solution for injection/infusion, Dacarbazin
Philogen S.p.A., PHILOGEN S.P.A., Philogen S.p.A.,
Unresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens, Soft-tissue sarcoma after failure of at least two prior systemic therapy regimens, Diseases [C] - Cancer [C04]
 
 
FLASH, NCT04733183 / 2018-004104-19: Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

Active, not recruiting
2
98
Europe
Dacarbazine, DTIC, onfekafusp alfa, L19TNF
Philogen S.p.A., Philogen S.p.A.,
Soft Tissue Sarcoma
12/25
12/25
GLIOSTELLA, NCT06336291: A Study with L19TNF in Combination with Lomustine in Patients with Glioblastoma At Progression or Recurrence

Recruiting
2
90
US
L19TNF, onfekafusp alfa, Lomustine
Philogen S.p.A.
Glioblastoma
06/26
06/26
FIBROSARC USA, NCT03420014: Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients

Recruiting
2
114
US
Doxorubicin, L19TNF plus doxorubicin
Philogen S.p.A.
Leiomyosarcoma
12/24
12/25
GLIOMOON, NCT03779230: Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse

Completed
1/2
20
Europe
L19TNF, onfekafusp alpha
Philogen S.p.A.
Glioma of Brain
06/23
06/23
GLIOSTAR, NCT04573192: A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

Recruiting
1/2
142
Europe
L19TNF, onfekafusp alfa, Lomustine
Philogen S.p.A.
Glioblastoma
03/25
12/25
GLIOSUN, NCT04443010: Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma

Recruiting
1/2
226
Europe
Onfekafusp alfa, L19TNF, Temozolomide, TMZ
Philogen S.p.A.
Glioblastoma
10/26
12/26
DOXO75, NCT04032964: Dose Finding Study of L19TNF and Doxorubicin in Patients With STS

Active, not recruiting
1
2
US
L19TNF, DOXORUBICIN
Philogen S.p.A.
Soft Tissue Sarcoma
12/24
12/24
GLIOASTRA, NCT05304663: Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression

Withdrawn
1
24
NA
Onfekafusp alfa, L19TNF, Lomustine
Philogen S.p.A.
Glioblastoma
12/24
12/24
dodekin (F8-IL12) / Philogen
DODEKA, NCT04471987: Safety and Early Signs of Efficacy of IL12-L19L19.

Recruiting
1
94
Europe
IL12-L19L19, Dodekin
Philogen S.p.A.
Advanced Solid Tumor, Metastatic Solid Tumor
12/25
12/25
Nidlegy (darleukin/fibromun) / Philogen
2021-003064-27: Study of the efficacy of intratumoral injections of L19IL2 + L19TNF followed by surgery to prevent or retard appearance of new metastases Estudio de la eficacia de las inyecciones intratumorales de L19IL2 + L19TNF seguidas de cirugía para prevenir o retrasar la aparición de nuevas metástasis

Not yet recruiting
3
186
Europe
Darleukin, Onfekafusp alfa, L19IL2, L19TNF, Solution for injection
Philogen S.p.A., Philogen S.p.A.
Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions Melanoma maligno de la piel en pacientes con melanoma localmente avanzado y completamente resecable con/sin terapia previa y presencia de lesiones inyectables cutáneas y/o subcutáneas o ganglionares, Patients with metastatic melanoma, eligible for surgical resection of all metastases and with presence of injectable cutaneous, subcutaneous and/or nodal lesions. Pacientes con melanoma metastásico, aptos para resección quirúrgica de todas las metástasis y con presencia de lesiones cutáneas inyectables, subcutáneas y/o ganglionares., Diseases [C] - Cancer [C04]
 
 
Neo-DREAM, NCT03567889 / 2021-003064-27: Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients

Recruiting
3
186
Europe, US
Daromun, Surgery, Adjuvant therapy
Philogen S.p.A., Philogen S.p.A.
Melanoma Stage IIIB/C
06/24
06/26
INTACT, NCT06284590: Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

Recruiting
2
162
US
L19IL2, bifikafusp alfa, L19TNF, onfekafusp alfa, L19IL2/L19TNF, Daromun, KEYTRUDA®, pembrolizumab
Philogen S.p.A., Merck Sharp & Dohme LLC
Melanoma Stage III, Melanoma Stage IV
07/28
07/28
DUNCAN, NCT04362722 / 2020-003299-42: Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients

Recruiting
2
40
Europe
L19IL2 +L19TNF, bifikafusp alfa + onfekafusp alfa
Philogen S.p.A., Philogen S.p.A.
Carcinoma, Basal Cell, Carcinoma, Cutaneous Squamous Cell
09/24
09/24
NCT07046728: Efficay and Safety of DAROMUN on Patient Treated by Intralesionnal Injection: DAROMEL

Not yet recruiting
N/A
70
Europe
Efficay and Safety of DAROMUN on patient treated by intralesionnal injection: DAROMEL
Centre Hospitalier Universitaire de Nice
Injections Intralesional
10/25
03/26
Tripokin (IL2-L19-TNF) / Philogen
No trials found
177Lu-OncoFAP-23 / Philogen
No trials found
PHC-102 / Philogen
No trials found
ABBV-022 / AbbVie
No trials found
177Lu-BiOncoFAP / Philogen
No trials found
FAP-IL12 / Philogen
No trials found
Undisclosed prostate cancer therapeutic / Philogen
No trials found
OncoFAP-GlyPro-MMAE / Philogen
No trials found

Download Options